CERS vs PSA · rev $201.3M vs rev $4.82B
Cerus Corporation (CERS) versus PSA (PSA) — a side-by-side from cached financials, not a winner call.
Cerus Corporation (CERS) is a medical devices company listed on US.
PSA (PSA) common stock.
Latest reported CERS revenue for 2024-12-31 was $201.3M. Net income was -$21.0M. Revenue was up 7.8% from 2023-12-31 to 2024-12-31. CERS currently screens at market cap $294.4M.
Latest reported PSA revenue for 2025-12-31 was $4.82B. Net income was $1.78B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. PSA currently screens at market cap $0.
CERS currently screens at market cap $294.4M. PSA currently screens at market cap $0.
Not investment advice. Open the CERS and PSA stock pages for the full models.
Not investment advice.